Method of diagnosing early-stage non-small cell lung cancer
AssigneeBioMark Cancer Systems Inc.
InventorsRashid Ahmed M. Bux, David Wishart
Life of this patent
Estimating the term…
Abstract
The present disclosure pertains to a method of diagnosing cancer and, in particular, to a method of diagnosing early-stage non-small cell lung cancer by measuring metabolite biomarkers in serum and plasma. In some aspects, the methods comprise determining the concentration metabolites from the group comprising β-hydroxybutyric acid, LysoPC 20:3, PC ae C40:6, citric acid, carnitine, Sand fumaric acid. In some aspects, the methods comprise determining the concentration metabolites from the group comprising β-hydroxybutyric acid, LysoPC 20:3, spermidine, and fumaric acid.
Claims58
A method, the method comprising determining the concentration of each metabolite of a group of metabolites in a biological sample from a subject, wherein the group of metabolites comprises:
- β-hydroxybutyric acid, LysoPC 20:3, PC ae C40:6, citric acid, carnitine, and fumaric acid;
- β-hydroxybutyric acid, LysoPC 20:3, PC ae C40:6, and fumaric acid;
- or β-hydroxybutyric acid, PC ae C40:6, citric acid, and carnitine.
The method of claim 1 or 3, wherein the group of metabolites consists essentially of β-hydroxybutyric acid, LysoPC 20:3, PC ae C40:6, and fumaric acid.
The method of claim 5, wherein a probability score that meets or exceeds a stage I threshold indicates that the subject has stage I non-small cell lung cancer.
The method of claim 42, wherein the non-small cell lung cancer is stage I or stage II non-small cell lung cancer.
A method, the method comprising determining the concentration of each metabolite of a group of metabolites in a biological sample from a subject, wherein the group of metabolites comprises β-hydroxybutyric acid, LysoPC 20:3, fumaric acid, and spermine.
Dependencies are inferred from the claim text.